In 1968, the World Health Organization published guidelines on the principles and practice of screening for disease, which are often referred to as the ‘Wilson and Jungner criteria’. These principles are still applicable today. With the onset of genetic screening, new controversies around screening emerged and in 2008, Andermann et al. synthesized and modified the Wilson criteria. Screening is a systematic attempt to select those who are at high risk of a specific disease from among apparently healthy individuals. The ultimate aim of screening is prevention of disease or to detect disease at an early, curable stage. There are many controversies about screening for cancer, such as the use of prostatic-specific antigen screening for prostate cancer, mammography screening for breast cancer, and debates around current screening for colorectal, lung, and cervical cancers. Controversies also exist with regard to the level of evidence required before screening for a disease is initiated. Even if there is a high level of evidence for efficacy and effectiveness, how the programme should be implemented needs careful consideration, particularly a clear understanding of benefits versus harms, potential or actual. In some countries, mass population screening programmes are implemented and in others, screening is dependent on access to health insurance. This chapter explores past and current screening activities among women for early detection and prevention of gynaecological cancers including cervical, ovarian, and endometrial cancers and discusses screening for vulval and vaginal cancer.